Published in Cancer Res on May 15, 2008
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05
The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol (2010) 3.57
TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol (2010) 2.61
T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res (2009) 2.43
Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol (2009) 2.31
IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells. J Immunol (2010) 2.12
The role of NKT cells in tumor immunity. Adv Cancer Res (2008) 2.05
Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci (2009) 1.87
Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin Cancer Res (2009) 1.86
Complexities of TGF-β targeted cancer therapy. Int J Biol Sci (2012) 1.84
The TGF-beta paradox in human cancer: an update. Future Oncol (2009) 1.79
Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev (2009) 1.68
Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res (2009) 1.64
Interleukin-17 and its expanding biological functions. Cell Mol Immunol (2010) 1.55
Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer (2010) 1.45
Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat (2008) 1.41
Mast cells mobilize myeloid-derived suppressor cells and Treg cells in tumor microenvironment via IL-17 pathway in murine hepatocarcinoma model. PLoS One (2010) 1.39
Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy. Cancer Res (2008) 1.38
Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res (2008) 1.31
TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res (2011) 1.30
Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res (2009) 1.27
TGF-β receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms. Cancer Discov (2011) 1.26
Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res (2009) 1.25
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J Clin Invest (2013) 1.21
IL-17RC: a partner in IL-17 signaling and beyond. Semin Immunopathol (2009) 1.14
IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. Cancer Cell Int (2011) 1.10
Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma. Neuro Oncol (2009) 1.10
Molecular mechanisms of mouse skin tumor promotion. Cancers (Basel) (2010) 1.09
Gastric mucosal interleukin-17 and -18 mRNA expression in Helicobacter pylori-induced Mongolian gerbils. Cancer Sci (2009) 1.09
Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci U S A (2009) 1.06
Smad4 deficiency in T cells leads to the Th17-associated development of premalignant gastroduodenal lesions in mice. J Clin Invest (2011) 1.05
Blockade of Wnt/β-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype. Sci Rep (2015) 1.04
Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer (2010) 1.03
Transforming growth factor-beta and matrix metalloproteinases: functional interactions in tumor stroma-infiltrating myeloid cells. ScientificWorldJournal (2014) 1.03
Potent tumor-specific protection ignited by adoptively transferred CD4+ T cells. J Immunol (2008) 1.03
IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep (2013) 1.03
Interleukin-17: a promoter in colorectal cancer progression. Clin Dev Immunol (2013) 1.00
IL-17 promotes immune privilege of corneal allografts. J Immunol (2010) 1.00
Role of TGF-β and the tumor microenvironment during mammary tumorigenesis. Gene Expr (2011) 0.97
The Ron receptor tyrosine kinase negatively regulates mammary gland branching morphogenesis. Dev Biol (2009) 0.97
Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. BMC Cancer (2011) 0.95
Molecular analysis of tumor-promoting CD8+ T cells in two-stage cutaneous chemical carcinogenesis. J Invest Dermatol (2009) 0.95
Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One (2011) 0.95
Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Res (2009) 0.95
Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF-β in breast cancer progression. Int J Cancer (2012) 0.94
Chemical inhibition of prometastatic lysyl-tRNA synthetase-laminin receptor interaction. Nat Chem Biol (2013) 0.92
Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis. J Bone Miner Res (2010) 0.92
Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host. Cancer Gene Ther (2012) 0.92
IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells. Sci Rep (2015) 0.92
Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. BMC Cancer (2014) 0.91
TGF-beta modulates the functionality of tumor-infiltrating CD8+ T cells through effects on TCR signaling and Spred1 expression. Cancer Immunol Immunother (2009) 0.91
Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Res (2012) 0.91
Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage? Expert Opin Biol Ther (2011) 0.90
Cancer stem cell targeted therapy: progress amid controversies. Oncotarget (2015) 0.88
Strategies to use immune modulators in therapeutic vaccines against cancer. Semin Oncol (2012) 0.86
Arthritis augments breast cancer metastasis: role of mast cells and SCF/c-Kit signaling. Breast Cancer Res (2013) 0.85
Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. J Immunother Cancer (2014) 0.84
Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in murine models of melanoma. Mediators Inflamm (2013) 0.83
High throughput screening of cytokines, chemokines and matrix metalloproteinases in wound fluid induced by mammary surgery. Oncotarget (2015) 0.83
Nrf2 Induces IL-17D to Mediate Tumor and Virus Surveillance. Cell Rep (2016) 0.82
Cell mediated immune responses through TLR4 prevents DMBA-induced mammary carcinogenesis in mice. Int J Cancer (2011) 0.82
Regulation of tumor immune surveillance and tumor immune subversion by tgf-Beta. Immune Netw (2009) 0.82
Reduced interleukin-17 and transforming growth factor Beta levels in peripheral blood as indicators for following the course of bladder cancer. Immune Netw (2014) 0.82
Prognostic significance of interleukin-17 in solid tumors: a meta-analysis. Int J Clin Exp Med (2015) 0.82
The complexities of TGF-β action during mammary and squamous cell carcinogenesis. Curr Pharm Biotechnol (2011) 0.81
Th17 responses are not induced in dextran sodium sulfate model of acute colitis. Immune Netw (2011) 0.81
Interleukin-17 Could Promote Breast Cancer Progression at Several Stages of the Disease. Mediators Inflamm (2015) 0.80
Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis. Oncoimmunology (2014) 0.80
Tc17 cells in patients with uterine cervical cancer. PLoS One (2014) 0.79
U87MG glioma cells overexpressing IL-17 acclerate early-stage growth in vivo and cause a higher level of CD31 mRNA expression in tumor tissues. Oncol Lett (2013) 0.79
Chemotherapeutic Targeting of the Transforming Growth Factor-β Pathway in Breast Cancers. Breast Cancer Manag (2015) 0.79
Elevated IL-17 and TGF-β Serum Levels: A Positive Correlation between T-helper 17 Cell-Related Pro-Inflammatory Responses with Major Depressive Disorder. Basic Clin Neurosci (2016) 0.79
Role of IL-17 in Glioma Progression. J Spine Neurosurg (2013) 0.77
Adenovirus-mediated LIGHT gene modification in murine B-cell lymphoma elicits a potent antitumor effect. Cell Mol Immunol (2010) 0.77
Eriobotrya japonica hydrophilic extract modulates cytokines in normal tissues, in the tumor of Meth-A-fibrosarcoma bearing mice, and enhances their survival time. BMC Complement Altern Med (2011) 0.77
Increased interleukin-17 transcripts in peripheral blood mononuclear cells, a link between T-helper 17 and proinflammatory responses in bladder cancer. Iran Red Crescent Med J (2015) 0.77
BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer. Cell Mol Life Sci (2016) 0.77
Ovarian cancer stroma: pathophysiology and the roles in cancer development. Cancers (Basel) (2012) 0.77
Emerging strategies for cancer immunoprevention. Oncogene (2015) 0.77
Tumor cell secretion of soluble factor(s) for specific immunosuppression. Sci Rep (2015) 0.76
Expression of Th1- Th2- and Th17-associated cytokines in laryngeal carcinoma. Oncol Lett (2016) 0.75
Combination epidermal growth factor receptor variant III peptide-pulsed dendritic cell vaccine with miR-326 results in enhanced killing on EGFRvIII-positive cells. Oncotarget (2017) 0.75
The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs. Oncoimmunology (2017) 0.75
Characterization and Clinical Implication of Th1/Th2/Th17 Cytokines Produced from Three-Dimensionally Cultured Tumor Tissues Resected from Breast Cancer Patients. Transl Oncol (2015) 0.75
IL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role. Eur J Rheumatol (2017) 0.75
Reduced levels of T-helper 17-associated cytokines in the serum of patients with breast cancer: indicators for following the course of disease. Cent Eur J Immunol (2016) 0.75
Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model. PLoS One (2017) 0.75
Temporal and spatial changes of cells positive for stem-like markers in different compartments and stages of human colorectal adenoma-carcinoma sequence. Oncotarget (2017) 0.75
Role of T helper 17 cytokines in the tumour immune inflammation response of patients with laryngeal squamous cell carcinoma. Oncol Lett (2017) 0.75
The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients. PLoS One (2017) 0.75
IL-17RC is critically required to maintain baseline A20 production to repress JNK isoform-dependent tumor-specific proliferation. Oncotarget (2017) 0.75
TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity (2006) 29.29
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 26.05
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity (2006) 10.53
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res (1992) 9.02
IL-23 promotes tumour incidence and growth. Nature (2006) 6.30
Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity (2006) 5.91
Deactivation of macrophages by transforming growth factor-beta. Nature (1988) 5.56
Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol (2006) 4.98
Interleukin-17 promotes angiogenesis and tumor growth. Blood (2002) 4.90
Transforming growth factor-beta in T-cell biology. Nat Rev Immunol (2002) 4.50
TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell (2005) 4.46
Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci U S A (2004) 4.12
Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol (2007) 3.81
Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med (2001) 3.74
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29
Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood (2002) 3.17
Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med (1987) 3.03
IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol (2005) 3.02
TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest (2003) 3.01
Monoclonal antibodies recognizing transforming growth factor-beta. Bioactivity neutralization and transforming growth factor beta 2 affinity purification. J Immunol (1989) 3.00
Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet (1995) 2.50
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res (2004) 2.35
Increased cancer risk after liver transplantation: a population-based study. J Hepatol (2001) 2.25
TGF-beta: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression. Cytokine Growth Factor Rev (2003) 2.20
The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog (1999) 2.17
Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res (2005) 2.06
Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res (2006) 2.01
Localized production of TGF-beta mRNA in tumour promoter-stimulated mouse epidermis. Nature (1988) 1.99
CD8+ IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. J Immunol (2006) 1.94
Essential roles of CD8+CD122+ regulatory T cells in the maintenance of T cell homeostasis. J Exp Med (2004) 1.89
A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection. Cancer Res (2007) 1.78
Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest (2003) 1.76
Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology (2001) 1.68
Dual role for TGF-beta1 in apoptosis. Cytokine Growth Factor Rev (2005) 1.60
Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res (2002) 1.60
Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6. J Leukoc Biol (2007) 1.52
Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol (2001) 1.51
Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. Blood (2004) 1.48
Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res (2005) 1.36
Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res (2006) 1.35
Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. Proc Natl Acad Sci U S A (2007) 1.26
Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev (2005) 1.19
Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer. Cancer Res (2006) 1.16
MEK1 signaling mediates transformation and metastasis of EpH4 mammary epithelial cells independent of an epithelial to mesenchymal transition. Cancer Res (2002) 1.15
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity. Clin Cancer Res (2004) 1.02
Induction of interleukin-6 in the epidermis of mice in response to tumor-promoting agents. Carcinogenesis (1994) 0.92
Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature (2008) 8.17
Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol (2006) 7.89
Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling. Nature (2010) 7.50
The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol (2009) 6.74
Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol (2007) 5.99
Commensal DNA limits regulatory T cell conversion and is a natural adjuvant of intestinal immune responses. Immunity (2008) 5.82
Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A (2006) 5.69
An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med (2009) 4.97
IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem (2007) 4.77
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med (2005) 4.60
CD4(+)CD25(+) regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J Exp Med (2002) 4.56
Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood (2007) 4.50
The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A (2003) 4.41
Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol (2011) 3.91
Janus kinases in immune cell signaling. Immunol Rev (2009) 3.60
Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity (2010) 3.52
Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood (2007) 3.33
Regulation of microRNA expression and abundance during lymphopoiesis. Immunity (2010) 3.29
Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest (2002) 3.24
Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci U S A (2003) 3.18
Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum (2007) 3.06
TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest (2003) 3.01
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med (2005) 3.01
Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell Metab (2011) 2.73
Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol (2007) 2.69
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity (2011) 2.64
Smad4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature (2006) 2.60
IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol (2004) 2.47
Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity (2012) 2.47
T(H)-17 differentiation: of mice and men. Nat Immunol (2007) 2.40
A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med (2005) 2.32
Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc Natl Acad Sci U S A (2003) 2.20
An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res (2008) 2.19
Genomic views of STAT function in CD4+ T helper cell differentiation. Nat Rev Immunol (2011) 2.09
Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell (2010) 2.06
Loss of Smad3 in acute T-cell lymphoblastic leukemia. N Engl J Med (2004) 2.05
The role of NKT cells in tumor immunity. Adv Cancer Res (2008) 2.05
Therapeutic targeting of Janus kinases. Immunol Rev (2008) 2.03
Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol (2009) 1.92
IL-15/IL-15Ralpha-mediated avidity maturation of memory CD8+ T cells. Proc Natl Acad Sci U S A (2004) 1.92
IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo. J Immunol (2011) 1.89
Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol (2007) 1.87
Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin Cancer Res (2009) 1.86
Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. J Clin Oncol (2005) 1.75
Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection. Nat Med (2012) 1.74
IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci U S A (2008) 1.72
Immunoregulatory T cells in tumor immunity. Curr Opin Immunol (2004) 1.69
Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol (2007) 1.67
Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One (2010) 1.66
Resistance to metastatic disease in STAT6-deficient mice requires hemopoietic and nonhemopoietic cells and is IFN-gamma dependent. J Immunol (2002) 1.66
Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines. Clin Cancer Res (2009) 1.64
Vaccine-induced myeloid cell population dampens protective immunity to SIV. J Clin Invest (2014) 1.64
Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis (2013) 1.64
Signal transduction pathways and transcriptional regulation in Th17 cell differentiation. Cytokine Growth Factor Rev (2010) 1.61
NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol (2007) 1.61
Distinct requirements for T-bet in gut innate lymphoid cells. J Exp Med (2012) 1.61
Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J Virol (2004) 1.59
Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res (2006) 1.59
Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res (2003) 1.59
Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest (2004) 1.58
Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest (2010) 1.58
A mouse model of HIES reveals pro- and anti-inflammatory functions of STAT3. Blood (2014) 1.58
Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood (2005) 1.54
Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol (2008) 1.52
Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines. Proc Natl Acad Sci U S A (2008) 1.51
Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother (2003) 1.51
T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol (2011) 1.47
NKT cells in tumor immunity: opposing subsets define a new immunoregulatory axis. J Immunol (2008) 1.46
TGF-beta1 production by CD4+ CD25+ regulatory T cells is not essential for suppression of intestinal inflammation. Eur J Immunol (2005) 1.46
Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer (2010) 1.45
Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol (2002) 1.44
Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum (2008) 1.43
The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med (2015) 1.42
Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res (2007) 1.42
Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res (2009) 1.41
The synthetic triterpenoid CDDO-Imidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res (2006) 1.40
Transforming growth factor-beta regulates house dust mite-induced allergic airway inflammation but not airway remodeling. Am J Respir Crit Care Med (2008) 1.40
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis (2003) 1.40
Progress on new vaccine strategies against chronic viral infections. J Clin Invest (2004) 1.38
Genome-wide association study identifies HLA-DP as a susceptibility gene for pediatric asthma in Asian populations. PLoS Genet (2011) 1.38
Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest (2004) 1.37
Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res (2006) 1.35